English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The effective use of drug-eluting stents (DES) in the treatment of ST-elevation myocardial infarction (STEMI), a condition representative of acute coronary syndrome, has not been clarified, particularly among Japanese patients. The indication of DES for STEMI patients is discussed by reviewing the evidence from both Western countries and Japan. Currently, in the registry studies, randomized studies, and meta-analyses comparing the use of DES and bare-metal stents (BMS) in STEMI patients, DES show a consistent trend toward decreasing the risk of repeat revascularization without increasing the incidence of death, recurrent MI or stent thrombosis when compared with BMS in the treatment for patients with STEMI. Japanese data are also consistent with this trend. However, there are no clear data indicating safety concerns. Longer-term follow-up studies are necessary to assess the effectiveness of DES in STEMI patients.

circulation journal

What Is the Effectiveness of Drug-Eluting Stents in the Treatment of ST-Elevation Myocardial Infarction? - Should Drug-Eluting Stents Be Indicated for Patients With Acute Coronary Syndrome? (Pro) -